Relative to the control group, or sorafenib or niclosamide alone, the combination of niclosamide and sorafenib had a significantly greater suppression effect on cell viability (Figure 2F and Supplementary Figure S4) and on the gene expression of IGF-1R, ABCG2, OCT4, and VIMENTIN (Figure 2G) in the sorafenib-resistant HCC organoids. The gene discussed is POU5F1; the disease is hepatocellular carcinoma.